<DOC>
	<DOCNO>NCT01181401</DOCNO>
	<brief_summary>This open-label , randomize , Phase II-study evaluate efficacy standard-TPF induction chemotherapy ( IC ) alternative TPF induction chemotherapy follow radio-antibody-therapy , patient unresectable LA-SCC HN region ( oro-hypopharynx carcinoma , cancer oral cavity ) . The primary objective study assess feasibility experimental 'fractionated ' TPF regimen compare current standard TPF regimen . Composite endpoint compliance feasibility term - response ( RECIST1.1 ) - hematological acute toxicity ( CTCAE v.4.02 ) - time application RAT follow experimental standard TPF IC . Secondary endpoint - Treatment intensity achieve - Toxicity ( accord CTCAE v.4.02 ) - Response rate completion induction chemotherapy completion entire protocol treatment ( RECIST1.1 ) - Survival ( progression-free , metastasis-free , recurrence-free , overall ) 1 year randomisation - Quality life accord EORTC QoL C30 &amp; HN35 The study conduct 5-6 investigational site Germany recruit 90 patient total . Eligible patient diagnosis histologically confirm SSC HN . Patients receive one 2 different regimen TPF IC follow cetuximab together radiotherapy ( RAT ) standard radiochemotherapy ( RCT ) regimen .</brief_summary>
	<brief_title>InductionChemo-Radio-Antibody-Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Histologically proven unresectable SCC oral cavity , oropharynx hypopharynx ( stage IVA &amp; IVB ) Written sign inform consent Karnofsky PS &gt; 70 % Age ≥ 18 year Curative treatment intent Adequate bone marrow , hepatic renal function evidence follow : Hematology ( Bone marrow ) : Neutrophils &gt; 2.0 109/L Platelets &gt; 100 x 109/L Hemoglobin &gt; 10 g/dL Hepatic function : Total serum bilirubin &lt; 1 time UNL participate center ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5 x UNL Alkaline phosphatase &lt; 5 x UNL Renal function : serum creatinine ( SC ) &lt; 120 µmol/L ( 1.4 mg/dl ) ; value &gt; 120 µmol/L , creatinine clearance &gt; 60 ml/min ( actual calculate CockcroftGault method follow : weight ( kg ) x ( 140 age ) K x serum creatinine serum creatinine mg/dL : K = 72 man K = 85 woman serum creatinine µmol/L : K = 0.814 man K = 0.96 woman • If childbearing potential , willingness use effective contraceptive method study duration 2 month postdosing . All patient require : dental examination appropriate dental preservation need 1 week prior begin radiotherapy , gastric feed tube Portalcatheter . Other neoplasia within past 5 year exception control skin cancer `` situ '' cervix cancer Unknown primary ( CUP ) , nasopharynx , laryngeal salivary gland cancer Distant metastatic disease ( M1 ) Serious comorbidity , e.g . arteriosclerosis apoplexy , recent myocardial infarction , highgrade carotid stenosis , unstable cardiac disease despite treatment , congestive heart failure NYHA grade 3 4 , insulindependent diabetes mellitus , uncontrolled hypertension , liver cirrhosis ( Quick &lt; 75 % , total protein &lt; 3.0 g/dl , bilirubin &gt; 2mg/ml ) kidney insufficiency ( creatinine &gt; 1.4 mg/ml , creatinine clearance &gt; 60 ml/min ) patient ASAT ALAT &gt; 2.5 UNL associate alkaline phosphatase &gt; 5 UNL eligible study Known HIVinfection Pregnancy lactation Women childbearing potential unclear contraception Previous treatment disease chemotherapy , radiotherapy , EGFRtargeting agent surgery exceed biopsy head neck Concurrent treatment experimental drug participation another clinical trial investigational drug within 30 day prior study screen Social situation limit compliance study requirement Deficient dental preservation status accomplish wound heal Legal incapacity Prior accommodation institution officially judicially order ( § 40 1 p. 3 No . 4 AMG ) Symptomatic peripheral neuropathy National Cancer InstituteCommon Toxicity Criteria ( NCICTC ) grade 2 and/or ototoxicity grade 2 , except due trauma mechanical impairment due tumor mass Known allergic/hypersensitivity reaction component treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>induction chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>locally advanced head neck tumor</keyword>
	<keyword>toxicity</keyword>
	<keyword>LA SCCHN</keyword>
	<keyword>Unresectable squamous cell cancer head neck ,</keyword>
	<keyword>Stage IV ( UICC )</keyword>
</DOC>